Comprehensive murine study confirms safety, complementing previous efficacy data on ActivePure’s continuous air and surface decontamination technology
DALLAS–(BUSINESS WIRE)–ActivePure Medical, a division of AP Sciences Group, LLC, a global provider of cutting-edge, continuous air and surface decontamination technology, today announced results from a safety study of its ActivePure Advanced Photohydrolysis Technology. The study, published in PLOS One, provides direct and comprehensive evidence of the safety of ActivePure’s proprietary photohydrolysis technology, for use in occupied indoor spaces. These findings support and encourage the continued adoption of this proven technology for reducing airborne and surface pathogens.
“Thorough examination of respiratory tissues revealed no adverse effects on physiology, even after continuous 90-day exposure. In an era marked by emerging global health threats, innovations like ActivePure Advanced Photohydrolysis Technology are essential for creating safer indoor environments.”
There is a pressing need for effective, continuous air cleaning and surface disinfection technologies, highlighted by recent public health crises. ActivePure Technology, as implemented in the Induct Guardian Series, has already demonstrated significant efficacy in reducing pathogens with a recent study published in the American Journal of Infection Control showing 96-99% reduction in methicillin-resistant Staphylococcus aureus (MRSA) and 70-71% decreases in healthcare-associated infections in hospital settings over 12-21 months.
This newly published data complements previous efficacy studies by demonstrating the safety of continuous use of the ActivePure Advanced Photohydrolysis Technology. The study utilized murine subjects due to their physiological similarities to humans. The 90-day safety study used a C57BL murine model, a strain chosen for its sensitivity to airborne substances and pronounced inflammatory responses. The mice were exposed to therapeutic levels of ActivePure’s Advanced Photohydrolysis Technology, with researchers monitoring behavior, weight gain, food consumption, blood chemistry and hematology, as well as conducting detailed histological examinations of respiratory tissues.
“This study provides detailed, direct evidence of the safety of advanced photohydrolysis technology using a mammalian model,” said Claude P. Selitrennikoff, Ph.D., the lead study author. “Thorough examination of respiratory tissues revealed no adverse effects on physiology, even after continuous 90-day exposure. In an era marked by emerging global health threats, innovations like ActivePure Advanced Photohydrolysis Technology are essential for creating safer indoor environments.”
Key findings include:
- No observable differences in behavior, weight gain, or food consumption between exposed and control mice
- Normal blood chemistry and hematology values in exposed mice
- No evidence of tissue damage, inflammation, or abnormalities in the respiratory tract of exposed mice
“ActivePure Technology has established through FDA clearance, lab testing, and real-world outcomes, that it is highly effective at remediating the six most infectious forms of pathogens,” said Joseph, P. Urso, CEO of AP Sciences Group, LLC. “The results of this research study bring further assurance to questions of safety that should be asked regarding every technology being used to protect health. We are delighted to share this study and build confidence, not only in the efficacy of ActivePure, but also in the peace of mind that can come from its implementation.”
Media Contacts:
For media inquiries please contact us at: PR@activepure.com
The original Story can be found on Businesswire.